Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

Related Keywords

Colorado ,United States ,Matthew Lunning ,Manali Kamdar ,Department Of Internal Medicine ,Division Of Oncology Hematology ,University Of Nebraska Medical Center ,Cell Therapies Center ,University Of Colorado ,Blood Club ,Lymphoma Services ,Internal Medicine ,Nebraska Medical Center ,Blood Disorders ,Anschutz Medical Campus ,O ,Naacp ,Patients With Hematologic Malignancies ,D ,Polarix Trial ,Nct03274492 ,Polar Chp ,Patients With Previously Untreated Diffuse Largeb Cell Lymphoma ,Anschutz Medical Campus At The University Of Colorado ,